A patient with prior delayed inflammatory reaction to BDDE-based fillers requested HA treatment three years after resolution.
A total of 2 ml was injected bilaterally into the lateral and mid-to-lower face using linear retrograde and fanning techniques. At 12-month follow-up, volume and skin quality were restored with no inflammatory recurrence.
Neauvia Stimulate (PEG-crosslinked HA 26 mg/ml + 1% CaHA) was chosen for safety and dual volumizing/biostimulatory action.
Neauvia products are for trained experts only. Use must follow approved indications and the Instructions for Use (IFU) in accordance to applicable laws and regulations in each country. Physicians are solely responsible for any treatments outside these conditions. The results shown are specific to an individual treatment plan. Treatment decisions must be adapted to each patient, who may respond differently based on numerous factors. Outcomes are variable and not guaranteed.